Cholesterol drug significantly reduced patients’ risk of death in trial, a boon for Sanofi and Regeneron
A cholesterol drug from Sanofi and Regeneron significantly reduced patients’ risk of death in a clinical trial, giving them a boost over rival Amgen.
A cholesterol drug from Regeneron Pharmaceuticals and Sanofi reduced patients’ risk of death in a major clinical trial, giving the companies a boost over rival Amgen and stoking hopes that the costly medicine might finally find commercial success.
The treatment, called Praluent, reduced the risk of death by 15 percent in a study involving 18,000 high-risk patients who had uncontrolled cholesterol despite taking a maximum amount of statins like
